The marketing for NAD+ therapy talks about benefits. Patients deciding whether to start a protocol need to understand the other side of the ledger: what the side effects actually look like, how dose-dependent they are, when they warrant attention, and who should not start the protocol at all. This article is the clinical version of that conversation. Nothing about it is alarming — NAD+ side effects are generally mild and dose-responsive — but the patient deciding whether to start should have an accurate picture before they do.
The honest assessment: NAD+ safety in healthy adults at clinical doses is well-established, the side effect pattern is predictable and dose-dependent, and the protocol can almost always be adjusted to manage tolerability problems without discontinuing entirely. The places where caution is genuinely warranted are specific medical contexts — active cancer treatment, certain cardiovascular conditions, pregnancy — where the calculus changes. The rest of the population tolerates the protocol at appropriately titrated doses with minimal disruption.
The flush response
The most discussed side effect is the NAD+ flush: a sensation of warmth, mild facial or chest redness, and occasional chest pressure that occurs during or shortly after a higher-dose administration. Patients describe it variably as feeling the dose travel through their body, a warm wave, or a sensation similar to a niacin flush at lower intensity.
The mechanism is not fully characterized in the literature. The leading explanations involve histamine release from mast cells responding to the sudden concentration increase, direct vasodilatory effects of NAD+ or its metabolites at higher concentrations, and possible contributions from rapid cofactor turnover at the cellular level. The phenomenology is consistent across patients even if the precise mechanism is still under investigation.
What matters clinically is that flush intensity is dose-dependent and rate-dependent. A 50 mg subcutaneous injection produces little to no flush in most patients. A 250 mg IV bolus delivered over 30 minutes produces strong flush in most patients. The same 250 mg delivered over 180 minutes produces meaningfully less. Slowing the rate or reducing the per-dose concentration almost always reduces the flush. Most patients find that the response diminishes after the first one or two sessions as tolerance develops, and the protocol becomes routine.
GI symptoms
Mild nausea is the second most commonly reported acute side effect, particularly during the first sessions of a higher-dose protocol or during rapid IV infusions. The pattern is similar to the flush — dose-dependent, rate-dependent, and typically transient. Most patients who experience nausea on the first session report it diminishing or disappearing on subsequent sessions.
Subcutaneous protocols at conservative starting doses rarely produce nausea. When patients on SubQ do report GI symptoms, the cause is more often the dose has been escalated too quickly, the injection has been administered into a poorly perfused site, or the patient is dehydrated or has eaten poorly before the dose. Adjustments to those variables typically resolve the symptom.
Persistent GI complaints across multiple sessions — vomiting, abdominal pain, or diarrhea — are uncommon and warrant clinician contact. They may indicate dose intolerance, an underlying condition that NAD+ is aggravating, or an unrelated cause. The clinician's first move is usually a dose reduction or extended interval between doses rather than discontinuation.
Headache
Some patients report headache during or shortly after higher-dose administrations. The pattern is similar to the flush in distribution and timing — frontal or temporal, mild to moderate intensity, resolving within a few hours. The mechanism is likely vasodilatory and shares some pathophysiology with the flush response itself.
A small fraction of patients develop a more persistent headache pattern that recurs across multiple sessions. This is a signal to slow the protocol: reduce per-dose concentration, lengthen the infusion or injection interval, or extend the gap between administrations. Most of these patients can find a dose and cadence that produces benefit without the headache.
Headache that worsens progressively, presents with neurological symptoms, or differs in character from the patient's baseline is not attributed to NAD+ without a more careful evaluation. The clinician will treat new neurological complaints as they would in any other context, regardless of whether the patient is on NAD+ at the time.
Injection site reactions
Subcutaneous protocols produce local site reactions in some patients: warmth, mild redness, occasional welts that resolve within hours, and tenderness for 12 to 48 hours after the injection. These are generally mild and resolve without intervention. Site rotation — alternating between abdomen, thigh, and other approved subcutaneous sites — reduces the cumulative impact on any single area.
A small fraction of patients develop more pronounced site reactions — larger areas of redness, persistent firmness under the skin, or itching that lasts longer than 48 hours. These warrant clinician contact. Adjustments to injection technique, depth, site selection, and the per-dose volume usually resolve the issue. Persistent significant site reactions across multiple injections may indicate a sensitivity to a component of the preparation and warrant a change of route or product.
IV protocols rarely produce site reactions beyond the venous access point. IM protocols can produce local soreness for 24 to 48 hours, particularly at higher doses, similar to other IM peptide injections.
Dose-dependent character
A pattern across all of the above is that severity tracks dose and rate. Lower doses, slower delivery, and longer intervals between sessions reduce the side effect burden almost universally. This is the basis for the clinical principle of starting low and titrating: the clinician sets a conservative initial dose, observes tolerability, and increases only if the patient tolerates the dose well and the response warrants escalation.
The patient who has been promised dramatic effects at high doses and pushes the protocol aggressively is the patient most likely to experience strong flush, nausea, and headache. The patient who runs the protocol at conservative doses and titrates over weeks rather than days experiences minimal side effects and similar long-term benefit. The pharmacology favors patience.
Contraindications and cautions
Several clinical contexts warrant caution or full avoidance.
Active cancer treatment is the most important. NAD+ supports cellular energy production indiscriminately — in healthy tissue and in malignant tissue. The theoretical concern is that supplemental NAD+ could support tumor metabolism in patients with active disease. The clinical evidence is incomplete, and prudent practice is to avoid initiating NAD+ therapy in patients undergoing active cancer treatment unless the protocol is specifically supervised by their oncology team.
Significant cardiovascular instability — recent myocardial infarction, uncontrolled arrhythmia, severe cardiomyopathy, or unstable angina — is a contraindication pending cardiology clearance. The vasodilatory effects of higher-dose NAD+ are minor in most patients but can be problematic in patients whose cardiovascular status is already fragile.
Pregnancy and active breastfeeding are contraindications because no controlled safety data exists in these populations. The molecule is endogenous and ubiquitous, but the absence of trial data means clinical practice defers initiation until after pregnancy and lactation conclude.
Specific medications warrant individualized review. The clinician assesses the medication list during intake and identifies any interactions that warrant adjustment.
When to stop
Stop and contact the clinician for: severe or persistent flushing that does not respond to dose reduction; persistent GI symptoms across multiple doses; headache that worsens progressively or presents with neurological changes; chest pain or significant cardiovascular symptoms during or after dosing; signs of allergic reaction such as rash beyond the injection site, breathing difficulty, or facial swelling; or any symptom severe enough to disrupt daily function.
The protocol can almost always be modified rather than discontinued. Dose reduction, route change, slower delivery, or extended cadence addresses most tolerability problems. Persistent inability to tolerate the protocol despite adjustment is a reason to stop. The clinician does not push patients through ongoing intolerance.
How TelePeptide handles tolerability
Conservative starting doses, individualized titration, and clinician access for tolerability questions are the default. Patients receive guidance on technique, site rotation, and what to expect at each step. Eligibility, dose, and cadence are physician-determined based on history, goals, and labs. Compounded preparations are sourced from licensed 503A pharmacies. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved. The program is built around making safe peptides accessible, not around pushing protocols.
FAQ
Common questions
What is the NAD+ flush and why does it happen?
The flush is a sensation of warmth, mild redness, and occasional chest pressure that some patients experience during or shortly after a higher-dose NAD+ administration. The mechanism is not fully characterized but appears to involve histamine release and possibly direct vasodilatory effects of the molecule at higher concentrations. The intensity is dose-dependent and route-dependent: faster IV infusions produce stronger flush than slow infusions or subcutaneous injections of equivalent dose. Most patients find that the flush diminishes after the first one or two administrations as tolerance develops, and that lower per-dose concentrations or slower delivery rates eliminate it almost entirely.
How common are GI side effects?
Mild nausea is the most commonly reported GI symptom, particularly during the first few sessions of a higher-dose protocol or during rapid IV infusions. It is less common with subcutaneous protocols at conservative starting doses. When nausea occurs it typically resolves within an hour of the dose and does not require intervention. Persistent or severe GI symptoms — vomiting, abdominal pain, or diarrhea — are uncommon and warrant clinician contact. They can indicate dose intolerance, an underlying GI condition that NAD+ is aggravating, or an unrelated cause that happens to coincide with the protocol.
Can NAD+ cause headaches?
Some patients report headache during or shortly after higher-dose administrations, particularly IV at faster infusion rates. The mechanism is likely vasodilatory and similar to the flush response. Headaches in this context are usually mild, frontal or temporal in distribution, and resolve within hours. Persistent headache across multiple doses is a signal to slow the protocol — reduce dose, lengthen infusion time, or extend the interval between administrations. Headache that worsens over time, presents with other neurological symptoms, or differs from the patient baseline is not assumed to be NAD+-related and is evaluated separately.
Who should not use NAD+ therapy?
Several groups warrant caution or avoidance. Patients in active cancer treatment should not use NAD+ outside of an oncology-supervised protocol because the molecule supports cellular energy in healthy and malignant tissue alike. Patients with significant cardiovascular instability — recent infarction, uncontrolled arrhythmia, or severe cardiomyopathy — should defer pending cardiology clearance. Pregnancy and active breastfeeding are contraindications because no controlled safety data exists in those populations. Patients on specific medications that interact with NAD+ pathways should be reviewed individually. The clinician makes these calls during intake based on history, labs, and current medications.
When should someone stop the protocol?
Stop and contact the clinician for severe or persistent flushing that does not respond to dose reduction, persistent GI symptoms across multiple doses, headache that worsens over time or presents with neurological changes, chest pain or significant cardiovascular symptoms during or after dosing, signs of allergic reaction such as rash beyond the injection site or breathing difficulty, or any symptom that is severe enough to disrupt daily function. The protocol can almost always be modified — dose reduction, route change, cadence adjustment — to address tolerability problems. Persistent inability to tolerate the protocol is a reason to discontinue rather than push through.
Next Step
Talk to a TelePeptide Clinician
A licensed clinician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
TelePeptide offers direct-pay telehealth services. All medications are compounded by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.